Search results
Horizon Therapeutics is a biotechnology company that is driven to deliver breakthrough medicines to patients because we understand the challenges they face.
- 116.30Add to watchlist0.00 (0.00%)At close: Thu. May 9, 2024 4:00 PM EDT · Delayed Quote (USD) · Market closed
- Open116.34High116.30Low116.30
- Mkt CapN/AP/E (TTM)N/ADiv & YieldN/A & N/A
- Prev. Close116.3052 Wk. Low116.3052 Wk. High116.30
Related stocks
Horizon Therapeutics was a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. [4]
THOUSAND OAKS, Calif., Oct. 6, 2023 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it has completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion.
Oct 6, 2023 · Oct 6 (Reuters) - Amgen (AMGN.O) said on Friday it had completed the $27.8 billion acquisition of Horizon Therapeutics (HZNP.O) after it received the go-ahead from the U.S. Federal Trade ...
Dec 12, 2022 · Key Points. Amgen will acquire Horizon Therapeutics, a biopharmaceutical company that focuses on treatments for rare, autoimmune diseases, in a deal valued at approximately $26.4 billion. Each ...
Sep 1, 2023 · WASHINGTON—The Federal Trade Commission said Friday it had agreed to end its legal challenge of drugmaker Amgen ’s AMGN -0.48% $27.8 billion deal to buy Horizon Therapeutics, averting a trial...
Dec 12, 2022 · Amgen Inc. agreed to buy Horizon Therapeutics Plc for about $27.8 billion in its biggest-ever acquisition, deepening its commitment to treatments for autoimmune, inflammatory and rare diseases...
